Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention among vulnerable populations in India: Findings from a qualitative study
PLOS One · 2025
DOI: 10.1371/journal.pone.0321725 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift PLOS One, 2025. Verfasst von Joyeeta Mukherjee und 16 weiteren Autor:innen. Beteiligte Einrichtung: IAVI, Gurugram, India. Hauptthemen laut MEDLINE: HIV Infections, Vulnerable Populations, Broadly Neutralizing Antibodies, Patient Acceptance of Health Care. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Agency for International Development.
Abstract (Originalsprache)
With newer advances in HIV biomedical research, the prevention toolbox is expanding with potential inclusion of long-acting anti-retrovirals, broadly neutralizing antibodies (bNAbs), and vaccines. While a multitude of prevention options provide diverse choice sets, they may potentially introduce conundrums and trade-offs which influence end-user decisions on acceptability. Thus, to maximize the unique value and uptake of new products, it is critical to understand contextual drivers of choice and relative product positioning. With HIV bNAbs in the pipeline, a qualitative study was conducted to understand end-users’ acceptability. 36 focus-group discussions (n=242) and 57 in-depth interviews were conducted in Chennai, Delhi and Mumbai, with female sex workers (FSWs), men who have sex with men (MSM), people who inject drugs (PWID) and transgender women (TGW) and adolescent girls and young women (AGYW). In addition, 15 simulated behavioral experiments (n=94) were conducted to delve deeper into factors influencing decision-making and potential avenues for intention-action gaps to understand preference construction and reversal pathways. Efficacy, frequency of administration and side-effects were the most important attributes driving acceptability. At least 70% to 90% efficacy was preferred. Arm was the most preferred site of administration (familiarity, maximum privacy), whereas buttocks were preferred by some (better pain tolerance, unhampered mobility). One injection every 3–6 months from community-based facilities was most preferred. Most did not favor self-administration (lack of self-efficacy, adverse events) and voiced confidence in community-friendly professionals. Concerns were raised about potential major side-effects such as interactions with co-morbidities, fertility, pregnancy, gender-affirmation therapy, physical appearance. When end-users were presented with hypothetical product profiles, all preferred the non-antiretroviral (non-ARV) based option which had arm as site of injection and administered every three months by healthcare workers. The preference construction journey revealed positive emotions and rational considerations which favoured bNAbs use but they were contrasted with negative emotions and rationale which hindered acceptability, and the users were faced with multiple conundrums. Some of these conundrums gave rise to potential scenarios of preference reversal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IAVI, Gurugram, India.
- Centre for Sexuality and Health Research and Policy (C-SHaRP), Chennai, India.
- Research Division, The Humsafar Trust, Mumbai, India.
- Implementation Research Division, Y.R. Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
- The Final Mile, Mumbai, India.
- Global Access, IAVI, New York, United States of America.
ORCID-Profile: Joyeeta Mukherjee, Alok Gangaramany
Förderung
- United States Agency for International Development
Zitieren
APA
Mukherjee, J., Ul Hadi, S., Chakrapani, V., Rawat, S., Srikrishnan, A. K., Mahendra, V., Baruah, D., Mohapatra, S., Gopinath, U., Dange, A., Rath, P., Manchi, P., Gangaramany, A., Aggarwal, P., Malhotra, S., Keane, M., & Goyal, R. (2025). Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention among vulnerable populations in India: Findings from a qualitative study. PLOS One. https://doi.org/10.1371/journal.pone.0321725
Vancouver
Mukherjee J, Ul Hadi S, Chakrapani V, Rawat S, Srikrishnan AK, Mahendra V, et al. Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention among vulnerable populations in India: Findings from a qualitative study. PLOS One. 2025. doi:10.1371/journal.pone.0321725
BibTeX
@article{Mukherjee2025,
author = {Mukherjee, Joyeeta and Ul Hadi, Saif and Chakrapani, Venkatesan and Rawat, Shruta and Srikrishnan, Aylur Kailasom and Mahendra, Vaishali and Baruah, Dicky and Mohapatra, Shobha and Gopinath, Usha and Dange, Alpana and Rath, Pratyasha and Manchi, Pallavi and Gangaramany, Alok and Aggarwal, Pritha and Malhotra, Shelly and Keane, Margaret and Goyal, Rajat},
title = {Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention among vulnerable populations in India: Findings from a qualitative study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321725}
}
EUVIMED